Royal Surrey County Hospital NHS Foundation Trust

March 31, 2021 Cheshire and Merseyside consortium (NHS) is the first region to have achieved this milestone for the UK’s National COVID-19 Chest Imaging Database (NCCID) The deployment of a single SMART box server has provided access to 15 years of imaging data across 2.5 million people in the region, the largest single data source for NCCID Data integration capabilities as a result of this deployment will allow Cheshire and Merseyside to validate the use of AI technology across a variety of conditions Amsterdam, the Netherlands and Guildford, United Kingdom – Royal Philips (NYSE: PHG, AEX: PHIA), today announced it has supported the NHS’ Cheshire and Merseyside consortium [1] to become the first regional hub supplying the United Kingdom’s National COVID-19 Chest Imaging Database (NCCID). The NCCID is a centralized database containing X-Ray, CT and MRI images from hospital patients across the country. It aims to support a better understanding of the COVID-19 virus and develop AI-powered technology which will enable the best care for patients hospitalized with a severe infection [2]. This first regional hub is integrating data across 13 NHS trusts in the consortium. The deployment of a single centralized and secure server has provided access to 15 years of imaging data across 2.5 million people in the region, the largest single data source for NCCID. The Cheshire and Merseyside consortium engaged with Philips to help with enabling access to the entire region’s imaging data through a single hub. Philips’ advanced data integration solution for radiology, Philips Global worklist , was used to enable easy integration with the NCIDD’s secure central SMART Box server that will be required to support mass data collection, management and de-identification and can facilitate multiple trials/research projects simultaneously. “One of the findings coming out of the end of this project will definitely be to focus on regional hubs that will be able to coordinate and better centralize the data, a hub just like Cheshire and Merseyside,” said Prof Mark-Halling Brown, Head of Scientific Computing at Royal Surrey NHS Foundation Trust. “It can take many months or even years to set up SMART boxes at individual trusts, so doing it regionally is the only way to scale up nationally.” “Most District General Hospitals average 250,000 to 350,000 imaging exams per year,” said Steve Sparks, Professional Services Manager Radiology Informatics at Philips UK&I. “With a single regional SMART box we have been able to gain access to the images from the 13 Trusts within the Cheshire and Merseyside consortium.” Save Radiologists’ time, increase the safety and consistency of care The NCCID database is developed in collaboration with NHSX , an organization driving the digital transformation of the NHS, The British Society of Thoracic Imaging (BSTI) and The Royal Surrey NHS Foundation Trust . The database is being used for the validation of AI products for use in the NHS, aiding the diagnosis and treatment of COVID-19 in the UK population. This data has the potential to enable quicker patient assessment when arriving at hospital’s emergency departments, save Radiologists’ time, increase the safety and consistency of care across the country, and ultimately save lives. It is being made available to researchers, clinicians, technology companies and all those wanting to investigate the disease and develop solutions that can support the COVID-19 patient care pathway. The SMART box server technology will also enable Cheshire and Merseyside to participate in research into many areas requiring large volumes of clinical imaging data. The COVID-19 pandemic has highlighted the potential for medical imaging systems powered by AI. The NHS AI Lab, created last year within NHSX, is developing a National Medical Imaging Platform with the purpose of creating a pipeline for patient data to be used within AI technology across conditions other than COVID-19. The NCCID is one workstream taken forward by the NHS AI Lab at NHSX, which will accelerate the safe, ethical, and effective adoption of AI in the healthcare sector. The power of large-scale data collection has already been demonstrated in various studies, including breast cancer screening studies such as OPTIMAM . Setting up regional hubs, such as the SMART box deployment in Cheshire and Merseyside, will aid the creation of these large-scale National databases and AI technology to help combat a variety of conditions. Comprehensive portfolio for COVID-19 high-quality care Philips has a comprehensive portfolio of products, services and solutions to support the delivery of high-quality care to COVID-19 patients worldwide. Solutions include secure, connected and intelligent approaches to diagnosis, treatment and predictive monitoring in the hospital, plus screening, remote patient monitoring and care at home. Philips’ telehealth and AI-enabled data analytics can help support workflows, facilitate remote collaboration and optimize resources. Philips’ COVID-19-related solutions are designed for rapid deployment and scalability. [1] Cheshire and Merseyside is a consortium group of 13 NHS trusts providing healthcare provision for a population of over 2.5 million people in the region. [2] For further information, please contact: Joost Maltha Philips Global Press Office Tel.: +31 6 10 55 81 16 E-mail: joost.maltha@philips.com Emily Wells-Burr Integrated Communications Manager, Philips UKI Tel: 07825 105 685 E-mail: emilywellsburr@philips.com About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 19.5 billion and employs approximately 82,000 employees with sales and services in more than 100 countries. News about Philips can be found at . Attachments

March 15, 2021 10:00 UTC VANCOUVER, British Columbia & SURREY, England--(BUSINESS WIRE)-- Biotech company SaNOtize Research & Development Corp., (SaNOtize), Ashford and St Peter’s Hospitals NHS Foundation Trust in Surrey, UK, and Berkshire and Surrey Pathology Services, UK, today announced results of clinical trials indicating that SaNOtize’s Nitric Oxide Nasal Spray (NONS) represents a safe and effective antiviral treatment that could prevent the transmission of COVID-19, shorten its course, and reduce the severity of symptoms and damage in those already infected. In a randomized, double-blind, placebo-controlled Phase 2 trial that evaluated 79 confirmed cases of COVID-19, SaNOtize’s early treatment for COVID-19 significantly reduced the level of SARS-CoV-2, including in patients with high viral loads. The average viral log reduction in the first 24 hours was 1.362, which corresponds to a decline of about 95%. Within 72 hours, the viral load dropped by more than 99%. The majority of these patients had been infected with the UK variant, which is considered a variant of concern. There were no adverse health events recorded in the UK trial, or in over 7,000 self-administered treatments given in earlier Canadian clinical trials. NONS is the only novel therapeutic treatment so far proven to reduce viral load in humans that is not a monoclonal antibody treatment. Monoclonal antibodies are highly specific, expensive and must be administered intravenously in a clinical setting. “I expect this to be a major advance in the global battle against the devastating human impacts of the COVID-19 pandemic,” said Dr. Stephen Winchester, Consultant Medical Virologist and Chief Investigator of this NHS Clinical Trial. “This simple portable nasal spray could be highly effective in the treatment of COVID-19 and reducing onward transmission. Our trial included patients with a variant of concern and high viral loads yet still demonstrated significant reductions in the levels of SARS-CoV-2, which could be critical in supporting vaccines, preventing future outbreaks and safely reopening economies. Simply stated, I think this could be revolutionary.” The SaNOtize treatment is designed to kill the virus in the upper airways, preventing it from incubating and spreading to the lungs. It is based on nitric oxide (NO), a natural nanomolecule produced by the human body with proven anti-microbial properties shown to have a direct effect on SARS-CoV-2, the virus that causes COVID-19. The pharmacology, toxicity, and safety data for NO use in humans has been well-established for decades. The NO molecule released from NONS is identical to the one delivered in its gaseous form to treat persistent pulmonary hypertension, or Blue Baby Syndrome, in newborn babies. SaNOtize Seeking Emergency Use Authorization in UK and Canada SaNOtize is applying to regulatory authorities in the UK and Canada for Emergency Use authorization. Swift approval and ramp-up of manufacturing could facilitate an almost immediate safe return to work, school and society, and spur an economic recovery that is months – if not years – ahead of full global vaccination. Wide-scale equitable global availability of NONS could form a bridge during the global production and distribution of vaccines to help keep people safe and healthy. The ease of NONS manufacture, storage and use makes NONS a treatment candidate that could soon be widely available at low-cost for long-term care facilities, healthcare and frontline workers, and the general population. In addition to providing antiviral treatment in the early stages of infection and for those who have yet to be vaccinated, NONS has also demonstrated that it could also reduce infectivity – the frequency of transmission from an infected person to a non-infected person. The results of the UK trial corroborate the information gathered from SaNOtize’s earlier Phase 2 trials in Canada and independent lab tests at Utah State University’s Antiviral Research Institute. “Now that NONS has been demonstrated to be safe and effective in clinical trials, we must move with urgency to get it into the hands of the public where it can help bring an end to the pandemic, accelerate a return to normality, and prevent future outbreaks of COVID-19 and its variants,” said Dr. Gilly Regev, CEO and co-founder of SaNOtize. “The human toll of this disease cannot be expressed simply in numbers, and each day compounds the frustration, fear and loss suffered by millions around the world. Combined with the roll-out of vaccines, NONS can help get the world back on its feet.” Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial -- Details This study, conducted by Dr Stephen Winchester and Dr Isaac John at Ashford and St. Peter’s Hospitals NHS Foundation Trust, was devised to determine the clinical efficacy of NONS for the treatment of mild COVID-19 infection. The primary outcome measure was the difference in SARS-CoV-2 RNA load from baseline through Day 6 between NONS and control arms. “NONS destroys the virus, blocks entry into and halts viral replication within the nasal cavity, which rapidly reduces viral load. This is significant because viral load has been linked to infectivity and poor outcomes,” said Dr. Chris Miller, Chief Science Officer and co-founder of SaNOtize. “There is currently a lack of an antiviral therapy that is effective against COVID-19 and its variants, can prevent or shorten the course of the disease, reduce damage, lower the severity of COVID-19, and can be made widely and readily available to the public. This is what makes NONS unique and enables it to stand alone from any other novel therapeutic application.” The study concluded that NONS accelerated clearance of SARS-CoV-2 by a factor of 16-fold versus the placebo, and it presents supporting evidence for the emergency use of NONS for prevention or treatment of patients with recent or established SARS-CoV-2 RNA infection during this COVID-19 pandemic. “The rigour of this trial and the decades of safety data behind nitric oxide gives us full confidence in requesting emergency use approval in the UK, Canada and elsewhere in the world.” said Rob Wilson, SaNOtize’s UK representative. “We are pleased to have conducted this crucial trial in the NHS and now hope that regulators will play their part in arming the public in the battle against this devastating disease.” About SaNOtize SaNOtize Research & Development Corp. is a biotech company based in Vancouver, BC working to commercialize the multi-faceted antimicrobial properties of a liquid producing nitric oxide. The company has developed and patented a Nitric Oxide Releasing Solution platform technology (NORSTM) to treat and prevent microbial infections. About Dr Stephen Winchester MSc MB BS FRCPath Dr. Winchester is Consultant Medical Virologist at Frimley Health NHS Foundation Trust. Affiliated with Berkshire and Surrey Pathology Services (BSPS). BSPS is a joint contractual venture between Ashford and St Peter's Hospitals NHS Foundation Trust, Frimley Health NHS Foundation Trust, Royal Berkshire NHS Foundation Trust and Royal Surrey County Hospital NHS Foundation Trust. About Robert Wilson Robert Wilson is a former government Minister and Member of Parliament for the United Kingdom. View source version on businesswire.com:

A number of UK universities, hospitals and companies are already embarking on research projects to harness the national Covid-19 imaging database While in vitro diagnostics has proved to be the main method for detecting the spread of Covid-19, medical imaging may now be more valuable in anticipating its severity - thanks to AI (Credit: Soloviova Liudmyla/Shutterstock) In the UK, the situation regarding Covid-19 is among the worst that can be seen anywhere in the world right now, making the introduction of a new, nationwide imaging database designed to help harness the potential of AI all the more welcome. The National Covid-19 Chest Imaging Database (NCCID), which consists of CT scans, MRIs and X-rays from more than 12,000 patients, is now accessible to hospitals and universities across the UK – several of which are already attempting to make the most of this resource using AI tools. The database features thousands of medical images taken during the pandemic, having been set up last year by NHSX – the government unit responsible for driving digital transformation in the NHS. Discussing the NCCID, Matt Hancock, UK Secretary of State for Health and Social Care, said recently: “The use of artificial intelligence is already beginning to transform patient care by making the NHS a more predictive, preventive and personalised healthcare service. “It is vital we always search for new ways to improve care, especially as we fight the pandemic with the recovery beyond. “This excellent work is a testament to how technology can help to save lives in the UK.” National Covid-19 Chest Imaging Database The NCCID is a centralised Covid-19 imaging database containing more than 40,000 medical scans from hospital patients across the country, making it one of the largest initiatives of its kind in the UK. It was jointly established by NHSX, the British Society of Thoracic Imaging (BSTI), and the Royal Surrey NHS Foundation Trust and Faculty, to support a better understanding of the novel coronavirus, which – as of 25 January – has resulted in 3.67 million infections and close to 100,000 deaths domestically. NHSX is also hoping researchers will be able to use this resource to develop new technologies that will make the earlier diagnosis of Covid-19 possible, therefore enabling the best possible care for patients hospitalised with a severe infection. At time of writing, there are a total of 20 NHS trusts contributing chest imaging data to the NCCID – including the University Hospitals NHS Foundation Trusts at Oxford and Cambridge, and Betsi Cadwaladr University Health Board, which is the largest health organisation in Wales. It was created by scaling up an existing data collection process that has previously been used to gather mammography data for research. One of its key features is the fact it de-identifies all of the data it holds at the point of collection, removing any potential legal or ethical complications regarding privacy, and patient confidentiality. The NCCID has been made available to researchers, clinicians, technology companies, and, according to NHSX, any other parties looking to investigate the virus and develop solutions to support the Covid-19 patient care pathway. How are UK hospitals and universities using the NCCID? Clinicians from the globally-renowned Addenbrooke’s Hospital in Cambridge have wasted little time in harnessing this new resource. By developing an algorithm based on NCCID data, the team is hoping to inform a more accurate diagnosis of patients when they present to hospital with potential Covid-19 symptoms, but have not yet had a confirmed test. Using visual signatures associated with the virus – which appear in chest scans – they have been able to compare patterns in a patient’s images with those seen previously in the NCCID, resulting in a more accurate diagnosis and prognosis. Carola-Bibiane Schönlieb, Professor of Applied Mathematics and head of the Cambridge Image Analysis group at the University of Cambridge, says: “The NCCID has been invaluable in accelerating our research and provided us with a diverse, well-curated, dataset of UK patients to use in our algorithm development. “The ability to access the data for 18 different trusts centrally has increased our efficiency, and ensures we can focus most of our time on designing and implementing the algorithms for use in the clinic for the benefit of patients. “By understanding – in the early stages of disease – whether a patient is likely to deteriorate, we can intervene earlier to change the course of their disease and potentially save lives as a result.” The NCCID is also helping researchers from several other universities – including University College London and the University of Bradford – to develop AI tools that could help doctors improve treatments for patients with Covid-19. In total, 13 different research projects utilising the database are currently underway – with UK-based tech firm V7 Labs, Dutch medical equipment manufacturer Aidence and Medical Analytica, a Welsh company that deploys AI in oncology screening, all attempting to anticipate the severity of Covid-19 infections more effectively, and ultimately improve detection of the virus. What are those involved saying about the database? In addition to Matt Hancock, several executives involved with the ongoing NCCID project have commented on its importance and the breakthroughs it could eventually enable in the earlier diagnosis of Covid-19. Dominic Cushnan, Head of AI Imaging at NHSX, says: “We are applying the power of artificial intelligence to quickly detect disease patterns and develop new treatments for patients. “There is huge potential for patient care, whether through quicker analysis of chest images or better identification of abnormalities. “The industrial scale collaboration of the NHS, research, and innovators on this project alone has demonstrated the huge potential and benefits of technology in transforming care.” Evis Sala, Professor of Oncological Imaging at the University of Cambridge, says: “The NCCID team have been extremely knowledgeable, helpful and responsive to our questions throughout the process. “This is precisely the initiative we need to ensure we are better prepared and more responsive for future pandemics.” Dr Mark Halling-Brown, Head of Scientific Computing at Royal Surrey County Hospital, says: “Royal Surrey NHS Foundation Trust has led the way in creating and sharing research imaging databases that have enabled the development of AI tools, and has more recently specialised in the evaluation and validation of AI radiology products within a range of specialities supporting their safe deployment into the clinic. “Our expertise allowed us to help build the National Covid-19 Chest Imaging Database, and we are excited by the potential of the AI solutions being developed and the research underway that will use this dataset.”